PRJNA772163
Deep sequencing of 8 off-target sites detected by WGS
We successfully develop a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. In the adoptive therapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, we observed durable responses without serious adverse events and complete remission in patients treated with these PD1 knockout CAR T cells. Here we applied deep sequencing to validate off-target events at 8 potential sites detected by WGS.